amniotic epithelial cells

Phase 1Biologic

TThe Second Affiliated Hospital of Fujian Medical University

amniotic epithelial cells is one of 12 biologic programs targeting Myelopathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyelopathyActive, not recruiting

MyelopathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Myelopathy

#DrugCompanyPhaseTrials

Immunoglobulin

Sanofi

Approved

1 2

Prialt

TTerezinha de Jesus Esteves Barata

Approved

1 3

Rilutek

AAzurity Pharmaceuticals

Phase 3

1 4

Rituxan

Roche

Phase 2

1 5

Ibudilast

UUniversity of California, Los Angeles

Phase 3

1 6

KW-0761

Kyowa Kirin Co., Ltd.

Phase 3

1 7

Methionine

SSt. Jude Children's Research Hospital

Phase 3

1 8

Zidovudine/lamivudine

Gilead

Phase 3

1 9

Limaprost

SSeoul National University Hospital

Phase 3

1 10

NK Cells

SSouthwest Hospital, China

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelopathy1 trial

Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM)

Unknown status·TThe Second Affiliated Hospital of Fujian Medical University·Phase 1·NCT02961712·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for amniotic epithelial cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — amniotic epithelial cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for amniotic epithelial cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Second Affiliated Hospital of Fujian Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TThe Second Affiliated Hospital of Fujian Medical University

amniotic epithelial cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myelopathy1 trial

References

Drug Info

Quick Facts

Related News